Mangoceuticals Regains Full Compliance With Nasdaq Minimum Bid Price Requirement
Mangoceuticals Regains Full Compliance With Nasdaq Minimum Bid Price Requirement
Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced that the Company received a letter on October 30, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Price Requirement").
Mangoceuticals, Inc.（NASDAQ:MGRX）（"MangoRx"或"公司"），是一家專注於通過安全遠程醫療平台開發、營銷和銷售男性健康與福祉產品的公司，今天宣佈公司於2024年10月30日收到了納斯達克股票交易所（"Nasdaq"）發來的一封信件，表明公司已恢復符合納斯達克依據納斯達克上市規則5550(a)(2)（"最低買盤價格要求"）繼續上市所需的最低買盤價格要求。
As indicated in the letter, Nasdaq determined that for 10 consecutive business days, the closing bid price of the Company's common stock was at or above $1.00 per share. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement and the matter is now closed.
正如信中所示，納斯達克確定公司普通股連續10個交易日的收盤買盤價格均達到或超過每股$1.00。因此，公司已符合最低買盤價格要求，此事已終結。
譯文內容由第三人軟體翻譯。
